SecBot SecBot
Insider Cluster (2 insiders) ·Filed Apr 17, 2026

KALV

KalVista Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizondays Processed7mo ago
Insider cluster: 2 insiders, $231K total
Actionable Insight ▼ Bearish

C-suite selling totaling $231K represents modest but notable insider divestment (~0.023% of $1.0B market cap). Monitor next earnings report for potential downward revisions or lack of catalysts that could explain profit-taking. Non-cash derivative exercises are routine, but open-market sales by CEO and CFO raise caution.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$20.48
T+0 close · Apr 16, 2026 · via day close
Latest settled
+30.66%
T+20 · $26.76
Vs SPY
+25.29%
α at T+20
Next horizon
T+60
due 4mo ago
  1. T+0 · Apr 17 $20.48entry
  2. T+1 · 7mo ago +1.90%α +2.10% · $20.87
  3. T+5 · 7mo ago −4.15%α −4.71% · $19.63
  4. T+20 · 6mo ago +30.66%α +25.29% · $26.76
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

KalVista Pharmaceuticals executives Palleiko (CEO) and Piekos (CFO) sold shares worth $231K in aggregate over a 7-day window, including open-market sales totaling $231K. The transactions follow derivative exercises, which are non-cash events.

Key Financial Metrics

Direction
selling
Total Value
$231.0K
Insiders
2

Key Facts

  • CEO Palleiko sold $193K of stock in open-market transactions on 2026-04-17.
  • CFO Piekos sold $38K of stock in open-market transactions on 2026-04-17.
  • Both executives also exercised derivatives (totaling $0 value) on 2026-04-16, which are routine non-cash events.
  • Total open-market selling by insiders: $231K over 7 days.

Financial Impact

$231,000 in open-market selling by C-suite executives

insider ownershipmarket sentiment

Risk Factors

  • Insider selling may signal lack of confidence in near-term prospects
  • Potential for negative market perception despite modest dollar size

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KALV-1776728476891

Track record

12 reports on KALV

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +0.45% at T+20 after the Apr 29, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Jun 22, 202621w ago 15-12G Bearish 7/10 No price data
  2. Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
  3. Jun 11, 202622w ago 8-K Neutral 5/10 Entry $26.99 No price data
  4. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
  5. May 19, 202625w ago Insider Cluster Bearish 5/10 Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
  6. May 19, 202625w ago Insider Cluster Neutral 2/10 Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
  7. Apr 29, 202628w ago 8-K Bullish 8/10 Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
  8. Apr 17, 202630w ago Insider Cluster Bearish 6/10 Viewing Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
  9. Feb 23, 202638w ago Insider Cluster Bearish 6/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
  10. Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026